Skip to main content
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences 1/2011

01.01.2011 | Original article

Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer

verfasst von: Koji Kitamura, Etsuro Hatano, Tatsuya Higashi, Satoru Seo, Yuji Nakamoto, Masato Narita, Kojiro Taura, Kentaro Yasuchika, Takashi Nitta, Kenya Yamanaka, Ryuichiro Doi, Iwao Ikai, Shinji Uemoto

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is used in the differential diagnosis and staging of extrahepatic bile duct cancer (EBDC), but its prognostic value has not been fully elucidated. In this study, we investigated the prognostic value of FDG-PET in EBDC patients.

Methods

The study included 73 consecutive patients with EBDC, of whom 48 underwent surgical resection for EBDC. The effects of clinicopathological factors including the standardized uptake value (SUV) of the primary lesion and lymph node metastasis detected by FDG-PET (PET-N) on overall survival were evaluated.

Results

In all 73 patients, multivariate analysis showed that surgical resection (risk ratio 2.5, 95% confidence interval [CI] 1.17–5.35, P = 0.018) and the SUV (2.0, 1.07–3.91, P = 0.030) were independent predictors of survival. In the 48 patients who underwent surgical resection, multivariate analysis revealed that perineural invasion (risk ratio 3.2, 95% CI 1.28–7.93, P = 0.012), pathologic lymph node metastasis (3.4, 1.27–9.17, P = 0.015), and PET-N (4.0, 1.10–15.25, P = 0.036) were independent predictors of overall survival. In the 25 patients without surgical resection, the SUV showed a significant relationship with overall survival (P = 0.014).

Conclusion

Our data suggest that the SUV of the primary lesion is a useful prognostic factor in patients with EBDC, and the prognosis for patients with PET-N remains very poor despite surgical resection.
Literatur
1.
Zurück zum Zitat Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefPubMed Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.CrossRefPubMed
2.
3.
Zurück zum Zitat Yee K, Sheppard BC, Domreis J, Blanke CD. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park). 2002;16(7):939–46, 949 (discussion 949–50, 952–3, 956–7). Yee K, Sheppard BC, Domreis J, Blanke CD. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park). 2002;16(7):939–46, 949 (discussion 949–50, 952–3, 956–7).
4.
Zurück zum Zitat Daines WP, Rajagopalan V, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 2. Oncology (Williston Park). 2004;18(8):1049–59. (discussion 1060, 1065–6, 1068). Daines WP, Rajagopalan V, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 2. Oncology (Williston Park). 2004;18(8):1049–59. (discussion 1060, 1065–6, 1068).
5.
Zurück zum Zitat de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–78.CrossRefPubMed de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–78.CrossRefPubMed
6.
Zurück zum Zitat Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498–501.CrossRefPubMed Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498–501.CrossRefPubMed
7.
Zurück zum Zitat Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39(5):883–917.CrossRefPubMed Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39(5):883–917.CrossRefPubMed
8.
Zurück zum Zitat Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32(1):35–46.CrossRefPubMed Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32(1):35–46.CrossRefPubMed
9.
Zurück zum Zitat Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029–35.CrossRefPubMed Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33(5):1029–35.CrossRefPubMed
10.
Zurück zum Zitat Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998;28(3):700–6.CrossRefPubMed Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998;28(3):700–6.CrossRefPubMed
11.
Zurück zum Zitat Widjaja A, Mix H, Wagner S, Graz KF, van den Hoff J, Petrich T, et al. Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis. Z Gastroenterol. 1999;37(8):731–3.PubMed Widjaja A, Mix H, Wagner S, Graz KF, van den Hoff J, Petrich T, et al. Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis. Z Gastroenterol. 1999;37(8):731–3.PubMed
12.
Zurück zum Zitat Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol. 2008;23(5):759–65.CrossRefPubMed Moon CM, Bang S, Chung JB, Park SW, Song SY, Yun M, et al. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol. 2008;23(5):759–65.CrossRefPubMed
13.
Zurück zum Zitat Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57–65.CrossRefPubMed Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2008;206(1):57–65.CrossRefPubMed
14.
Zurück zum Zitat Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29(8):1047–54.CrossRefPubMed Kato T, Tsukamoto E, Kuge Y, Katoh C, Nambu T, Nobuta A, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29(8):1047–54.CrossRefPubMed
15.
Zurück zum Zitat Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8(1):90–7.CrossRefPubMed Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8(1):90–7.CrossRefPubMed
16.
Zurück zum Zitat Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389–97.CrossRefPubMed Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, et al. Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2005;32(4):389–97.CrossRefPubMed
17.
Zurück zum Zitat Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30(9):1736–41.CrossRefPubMed Hatano E, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg. 2006;30(9):1736–41.CrossRefPubMed
18.
Zurück zum Zitat Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31(6):1256–63.CrossRefPubMed Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31(6):1256–63.CrossRefPubMed
19.
Zurück zum Zitat Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma, 2nd English edn. Tokyo: Kanehara; 2004. Japanese Society of Biliary Surgery. Classification of biliary tract carcinoma, 2nd English edn. Tokyo: Kanehara; 2004.
20.
Zurück zum Zitat Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21(1):19–22.CrossRefPubMed Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21(1):19–22.CrossRefPubMed
21.
Zurück zum Zitat Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38(9):1337–44.PubMed Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38(9):1337–44.PubMed
22.
Zurück zum Zitat Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143(6):769–77.CrossRefPubMed Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery. 2008;143(6):769–77.CrossRefPubMed
23.
Zurück zum Zitat Furukawa H, Ikuma H, Asakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100(6):494–9.CrossRefPubMed Furukawa H, Ikuma H, Asakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100(6):494–9.CrossRefPubMed
24.
Zurück zum Zitat Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22(12):1277–85.CrossRefPubMed Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schafer H, Buchert R, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22(12):1277–85.CrossRefPubMed
25.
Zurück zum Zitat Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317–23.CrossRefPubMed Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29(10):1317–23.CrossRefPubMed
26.
Zurück zum Zitat Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86(4):512–6.CrossRefPubMed Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86(4):512–6.CrossRefPubMed
27.
Zurück zum Zitat Dhital K, Saunders CA, Seed PT, O’Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18(4):425–8.CrossRefPubMed Dhital K, Saunders CA, Seed PT, O’Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg. 2000;18(4):425–8.CrossRefPubMed
28.
Zurück zum Zitat Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26(5):1335–53.CrossRefPubMed Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26(5):1335–53.CrossRefPubMed
29.
Zurück zum Zitat Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145–51.CrossRefPubMed Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103(5):1145–51.CrossRefPubMed
30.
Zurück zum Zitat Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol. 2005;31(10):1175–9.CrossRefPubMed Wakabayashi H, Akamoto S, Yachida S, Okano K, Izuishi K, Nishiyama Y, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol. 2005;31(10):1175–9.CrossRefPubMed
31.
Zurück zum Zitat Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006;70(5):358–65.CrossRefPubMed Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006;70(5):358–65.CrossRefPubMed
32.
Zurück zum Zitat Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227(3):405–11.CrossRefPubMed Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg. 1998;227(3):405–11.CrossRefPubMed
33.
Zurück zum Zitat Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241(5):703–12. (discussion 12–4).CrossRefPubMed Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005;241(5):703–12. (discussion 12–4).CrossRefPubMed
34.
Zurück zum Zitat Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6(2):108–16.CrossRefPubMed Isaji S, Kawarada Y, Taoka H, Tabata M, Suzuki H, Yokoi H. Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg. 1999;6(2):108–16.CrossRefPubMed
35.
Zurück zum Zitat Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233(3):385–92.CrossRefPubMed Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg. 2001;233(3):385–92.CrossRefPubMed
36.
Zurück zum Zitat Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15(1):41–54.CrossRefPubMed Kondo S, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, et al. Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment. J Hepatobiliary Pancreat Surg. 2008;15(1):41–54.CrossRefPubMed
37.
Zurück zum Zitat Nakamoto Y, Chang AE, Zasadny KR, Wahl RL. Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer. Mol Imaging Biol. 2002;4(2):161–9.CrossRefPubMed Nakamoto Y, Chang AE, Zasadny KR, Wahl RL. Comparison of attenuation-corrected and non-corrected FDG-PET images for axillary nodal staging in newly diagnosed breast cancer. Mol Imaging Biol. 2002;4(2):161–9.CrossRefPubMed
38.
Zurück zum Zitat Ebata T, Watanabe H, Ajioka Y, Oda K, Nimura Y. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89(10):1260–7.CrossRefPubMed Ebata T, Watanabe H, Ajioka Y, Oda K, Nimura Y. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg. 2002;89(10):1260–7.CrossRefPubMed
39.
Zurück zum Zitat Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240(1):95–101.CrossRefPubMed Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study. Ann Surg. 2004;240(1):95–101.CrossRefPubMed
40.
Zurück zum Zitat Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103(6):1210–6.CrossRefPubMed Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer. 2005;103(6):1210–6.CrossRefPubMed
Metadaten
Titel
Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer
verfasst von
Koji Kitamura
Etsuro Hatano
Tatsuya Higashi
Satoru Seo
Yuji Nakamoto
Masato Narita
Kojiro Taura
Kentaro Yasuchika
Takashi Nitta
Kenya Yamanaka
Ryuichiro Doi
Iwao Ikai
Shinji Uemoto
Publikationsdatum
01.01.2011
Verlag
Springer Japan
Erschienen in
Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 1/2011
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-010-0293-1

Weitere Artikel der Ausgabe 1/2011

Journal of Hepato-Biliary-Pancreatic Sciences 1/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.